Patent ID: 9072757
Filing Date: 2015-07-07
Classification: A61K,A61P,A61Q

Abstract:
1. A method of treating Progeria or restrictive dermopathy, the method comprising administering to a subject in need thereof, a pharmaceutical composition comprising a synergistically effective amount of a combination of an inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase and an inhibitor of farnesylpyrophosphate synthase, wherein the inhibitor of HMG-CoA is selected from the group consisting of pravastatin, atorvastatin, simvastatin, rivastatin, mevastatin, fluindostatin, velostatin, fluvastatin, dalvastatin, cerivastatin, pentostatin, rosuvastatin, pitavastatin, lovastatin, and a pharmaceutically acceptable salt thereof, and the inhibitor of farnesylpyrophosphate synthase is selected from the group consisting of: aledronic acid or its ionic form, alendronate; clodronic acid or its ionic form, clodronate; etidronic acid or its ionic form, etidronate; ibandronic acid or its ionic form, ibandronate; medronic acid or its ionic form, medronate; neridronic acid or its ionic form, neridronate; olpadronic acid or its ionic form, olpadronate; pamidronic acid or its ionic form, pamidronate; risedronic acid or its ionic form, risedronate; tiludronic acid or its ionic form, tiludronate; 4-N,N-dimethylaminomethane diphosphonic acid or its ionic form; dimethylaminomethanediphosphonate; and α-amino- (4hydroxybenzylidene) diphosphonate.